Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8931 in mild to moderate Alzheimer's disease
NL-OMON43729Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of verubecestat in Alzheimer's disease (AD) (4 arms), sponsored by Merck & Co. Primary endpoints: Change from baseline in ADAS-Cog at Week 78, Change from baseline in ADCS-ADL at Week 78 and 3 more. Started Jan 2013; status: active, not recruiting.
02
Drugs
verubecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON43729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43729.